Cargando…

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

The aims of this phase I/II study of docetaxel and S-1 were to determine the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), and recommended dose (RD) in the phase I part and to explore the tumour response, survival and safety in the phase II part. Patients with histologically- or cytolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, K, Shimamura, T, Hyodo, I, Koizumi, W, Doi, T, Narahara, H, Komatsu, Y, Kato, T, Saitoh, S, Akiya, T, Munakata, M, Miyata, Y, Maeda, Y, Takiuchi, H, Nakano, S, Esaki, T, Kinjo, F, Sakata, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361339/ https://www.ncbi.nlm.nih.gov/pubmed/16773074 http://dx.doi.org/10.1038/sj.bjc.6603196

Ejemplares similares

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
por: Koizumi, W., et al.
Publicado: (2010)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study
por: Okada, S, et al.
Publicado: (1999)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
por: Koizumi, W, et al.
Publicado: (2013)

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
por: Koizumi, W, et al.
Publicado: (2014)

Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis
por: Fushida, S., et al.
Publicado: (2013)

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)

Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity
por: Yamada, A, et al.
Publicado: (2014)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Possible metabolic interaction between docetaxel and ifosfamide
por: Ando, Y
Publicado: (2000)

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
por: Narahara, Hiroyuki, et al.
Publicado: (2011)

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
por: Kato, K., et al.
Publicado: (2021)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma.
por: Maeda, K., et al.
Publicado: (1995)

Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells
por: Fuyuhiro, Y, et al.
Publicado: (2011)

Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody.
por: Ohnishi, Y., et al.
Publicado: (1995)

Review of docetaxel in the treatment of gastric cancer
por: Tetzlaff, Eric D, et al.
Publicado: (2008)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
por: Nakata, B., et al.
Publicado: (1998)

Clinical significance of serum CYFRA 21-1 in gastric cancer.
por: Nakata, B., et al.
Publicado: (1996)

RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma
por: Kurashige, J, et al.
Publicado: (2012)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
por: Okamoto, W., et al.
Publicado: (2022)

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
por: Thuss-Patience, P C, et al.
Publicado: (2011)

Data to establish the optimal standard regimen and predicting the response to docetaxel therapy
por: Moawad, Emad Y.
Publicado: (2015)

A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)
por: Kunitoh, H, et al.
Publicado: (2008)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
por: Sulkes, A., et al.
Publicado: (1994)

Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis
por: Choi, Hong Y., et al.
Publicado: (2021)

Efficacy of early administration of thrombomodulin alfa in patients with sepsis-induced disseminated intravascular coagulation: subanalysis from post-marketing surveillance data
por: Eguchi, Y, et al.
Publicado: (2014)

Presentation and management of docetaxel-related adverse effects in patients with breast cancer
por: Ho, Maria Y, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ppj3i0nhr3kcmvofoq6p2b0nki